- Home
- MRSN vs ACET Comparison
MRSN vs ACET Comparison
Compare MRSN & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- ACET
- Stock Information
- Founded
- MRSN 2001
- ACET 1947
- Country
- MRSN United States
- ACET United States
- Employees
- MRSN N/A
- ACET N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- MRSN Health Care
- ACET Health Care
- Exchange
- MRSN Nasdaq
- ACET Nasdaq
- Market Cap
- MRSN 71.9M
- ACET 83.2M
- IPO Year
- MRSN 2017
- ACET N/A
- Fundamental
- Price
- MRSN $0.53
- ACET $0.98
- Analyst Decision
- MRSN Buy
- ACET Buy
- Analyst Count
- MRSN 7
- ACET 5
- Target Price
- MRSN $6.00
- ACET $5.67
- AVG Volume (30 Days)
- MRSN 5.4M
- ACET 1.6M
- Earning Date
- MRSN 03-07-2025
- ACET 03-18-2025
- Dividend Yield
- MRSN N/A
- ACET N/A
- EPS Growth
- MRSN N/A
- ACET N/A
- EPS
- MRSN N/A
- ACET N/A
- Revenue
- MRSN $34,837,000.00
- ACET N/A
- Revenue This Year
- MRSN N/A
- ACET N/A
- Revenue Next Year
- MRSN N/A
- ACET N/A
- P/E Ratio
- MRSN N/A
- ACET N/A
- Revenue Growth
- MRSN N/A
- ACET N/A
- 52 Week Low
- MRSN $0.49
- ACET $0.81
- 52 Week High
- MRSN $6.28
- ACET $2.61
- Technical
- Relative Strength Index (RSI)
- MRSN 32.86
- ACET 57.01
- Support Level
- MRSN $0.56
- ACET $0.84
- Resistance Level
- MRSN $0.82
- ACET $1.04
- Average True Range (ATR)
- MRSN 0.07
- ACET 0.08
- MACD
- MRSN 0.03
- ACET 0.01
- Stochastic Oscillator
- MRSN 8.39
- ACET 68.65
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.